Prolife Industries

₹208 0 | 0%

WEBSITE BSE:0 NSE : 17 May, 00:00

Market Cap ₹85 Cr.

Stock P/E 0.0

P/B 2.6

Current Price ₹208

Book Value ₹ 79

Face Value 10

52W High ₹337.6

Dividend Yield 0.14%

52W Low ₹ 188.7

Edit Ratio

Prolife Industries Research see more...

Overview Inc. Year: 1994Industry: Chemicals

Prolife Industries Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Prolife Industries Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Prolife Industries Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Net Sales	16	19	20	22	27	27	30	50	73	73	78
Other Income	0	0	0	1	0	0	0	2	1	2	2
Total Income	17	19	20	23	27	28	30	52	74	75	80
Total Expenditure	15	17	18	21	25	24	25	45	65	67	70
Operating Profit	1	2	2	2	3	4	5	7	9	8	11
Interest	0	1	1	1	1	1	1	1	1	0	0
Depreciation	0	0	0	0	0	1	1	1	1	1	1
Exceptional Income / Expenses	0	0	0	-0	0	0	0	0	0	0	0
Profit Before Tax	0	0	1	1	1	2	3	6	7	6	9
Provision for Tax	0	0	0	0	0	1	1	2	2	2	2
Profit After Tax	0	0	0	1	1	2	2	4	5	4	7
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	0	0	0	1	1	2	2	4	5	4	7
Adjusted Earnings Per Share	0	0	0	0	2.1	3.7	5	9.9	13.4	10.5	16.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	7%	16%	24%	17%
Operating Profit CAGR	38%	16%	22%	27%
PAT CAGR	75%	21%	28%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-1%	57%	55%	NA%
ROE Average	24%	24%	24%	18%
ROCE Average	30%	28%	27%	20%

Prolife Industries Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2	3	3	4	9	10	12	16	21	26	32
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	8	10	9	7	7	6	8	5	5	5	4
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0	0
Total Current Liabilities	3	4	6	5	3	5	6	14	22	24	4
Total Liabilities	14	16	18	16	18	21	27	36	49	55	41
Fixed Assets	2	2	3	3	6	7	8	7	7	9	9
Other Non-Current Assets	4	4	4	5	4	6	7	12	17	17	14
Total Current Assets	8	10	11	8	9	8	12	17	25	30	18
Total Assets	14	16	18	16	18	21	27	36	49	55	41

Prolife Industries Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	0	0	0	0	0	1	1	3	1	1
Cash Flow from Operating Activities	-4	0	3	4	-0	6	1	10	5	4	0
Cash Flow from Investing Activities	-1	-1	-1	-1	-3	-3	-2	-5	-6	-3	1
Cash Flow from Financing Activities	5	1	-2	-3	3	-2	2	-4	-1	-0	-1
Net Cash Inflow / Outflow	-0	-0	0	-0	-0	1	0	2	-2	1	0
Closing Cash & Cash Equivalent	0	0	0	0	0	1	1	3	1	1	1

Prolife Industries Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0	0	0	0	2.14	3.68	4.97	9.87	13.43	10.51	16.89
CEPS(Rs)	1.71	1.91	2.58	3.17	3.29	5.84	7.23	12.39	15.71	13.33	19.94
DPS(Rs)	0.4	0.3	0.2	0.2	0.2	0.25	0.3	0.3	0.3	0.3	0.3
Book NAV/Share(Rs)	0	0	0	0	21.21	24.64	29.62	39.12	52.25	62.46	79.04
Core EBITDA Margin(%)	5.86	8.34	9.35	8.03	9.32	12.84	14.17	11.03	11.18	8.17	11.15
EBIT Margin(%)	5.27	7.38	8.87	8.16	7.95	10.62	12.6	12.52	10.76	8.81	12.34
Pre Tax Margin(%)	2.33	2.42	3.04	3.65	4.87	7.66	9.52	11.26	10.04	8.16	11.79
PAT Margin (%)	1.52	1.47	1.9	2.36	3.22	5.51	6.86	8.01	7.47	5.88	8.83
Cash Profit Margin (%)	3.11	3	3.93	4.25	4.95	8.75	9.98	10.05	8.74	7.46	10.43
ROA(%)	2.06	1.84	2.2	3.11	5.07	7.6	8.52	12.96	13.05	8.27	14.33
ROE(%)	12.03	11.01	12.95	15.7	14.25	16.03	18.33	28.7	29.4	18.32	23.87
ROCE(%)	9.51	11.52	13.54	14.32	16.66	20.24	21.87	29.37	31.27	22.56	29.93
Receivable days	45.18	48.25	57.01	59.22	54.72	47.57	67.53	55.49	57.03	81.18	63.78
Inventory Days	79.11	105.38	115.6	77.71	38.28	39.4	33.19	30.6	35.76	48.22	40.11
Payable days	71.19	63.71	85.81	70.21	63.96	91.13	103.81	71.82	93.01	138.22	88.82
PER(x)	0	0	0	0	19.9	8.66	5.36	3.48	3.77	15.78	0
Price/Book(x)	0	0	0	0	2	1.29	0.9	0.88	0.97	2.65	0
Dividend Yield(%)	0	0	0	0	0.47	0.78	1.13	0.87	0.59	0.18	0
EV/Net Sales(x)	0.65	0.59	0.57	0.44	0.82	0.62	0.57	0.38	0.35	0.97	0.06
EV/Core EBITDA(x)	9.49	6.62	5.21	4.24	8.42	4.46	3.64	2.6	2.87	9.36	0.42
Net Sales Growth(%)	34.66	15.37	3.35	13.82	21.96	0.39	8.69	70.05	45.37	-0.24	7.03
EBIT Growth(%)	83.76	61.39	24.31	4.66	18.89	34.13	28.91	68.93	25.3	-18.53	49.82
PAT Growth(%)	43.09	12.1	33.3	41.15	66.44	72.1	35.27	98.4	36.16	-21.77	60.7
EPS Growth(%)	0	0	0	0	0	72.1	35.27	98.4	36.16	-21.77	60.7
Debt/Equity(x)	3.88	3.71	3.26	2.4	0.58	0.48	0.59	0.48	0.26	0.18	0.06
Current Ratio(x)	2.33	2.53	1.95	1.53	3.11	1.58	2.04	1.19	1.12	1.22	4.28
Quick Ratio(x)	0.88	0.91	0.83	0.92	2.22	0.89	1.7	0.73	0.77	0.75	2.9
Interest Cover(x)	1.79	1.49	1.52	1.81	2.58	3.59	4.09	9.97	15.12	13.53	22.63
Total Debt/Mcap(x)	0	0	0	0	0.29	0.37	0.66	0.55	0.27	0.07	0

Prolife Industries Shareholding Pattern

#	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Mar 2024
Promoter	73.74	73.74	73.74	73.74	73.74	73.74	73.74	73.74	73.74	73.74
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	26.26	26.26	26.26	26.26	26.26	26.26	26.26	26.26	26.26	26.26
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Mar 2024
Promoter	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11
Others	0	0	0	0	0	0	0	0	0	0
Total	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41	0.41

Pros

Company has delivered good profit growth of 28% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 24%
Debtor days have improved from 138.22 to 88.82days.
Company has reduced debt.
Company is almost debt free.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.